Anzeige
Mehr »
Mittwoch, 25.06.2025 - Börsentäglich über 12.000 News
TAO +1.800?%, SBAR +85?%, CYK +280?% - jetzt startet KORA auf Unternehmensebene durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWZV | ISIN: US45339J1051 | Ticker-Symbol:
NASDAQ
25.06.25 | 21:59
0,360 US-Dollar
-18,20 % -0,080
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
INDAPTUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
INDAPTUS THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur INDAPTUS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13:59Indaptus Therapeutics Sets 1-for-28 Reverse Stock Split-
INDAPTUS THERAPEUTICS Aktie jetzt für 0€ handeln
13:06Indaptus Therapeutics Announces Reverse Stock Split29NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer...
► Artikel lesen
13.06.Indaptus Therapeutics announces sale of $2.3M of convertible notes, warrants2
13.06.Indaptus Therapeutics raises $2.3 million through convertible notes2
13.06.Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants1
11.06.Indaptus Therapeutics, Inc. - 8-K, Current Report1
14.05.Indaptus Therapeutics GAAP EPS of -$0.32 misses by $0.141
14.05.Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update110NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer...
► Artikel lesen
14.05.Indaptus Therapeutics, Inc. - 10-Q, Quarterly Report1
14.05.Indaptus Therapeutics, Inc. - 8-K, Current Report1
25.03.Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit2
18.03.Indaptus Therapeutics Stock Gains 8% On Clinical Trial Expansion3
18.03.EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors5
13.03.Indaptus Therapeutics GAAP EPS of -$1.613
13.03.Indaptus Therapeutics, Inc. Full Year Loss Narrows3
13.03.Indaptus Therapeutics, Inc. - 8-K, Current Report1
13.03.Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update157Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20Pharmacodynamic immune activation biomarker and pharmacokinetics profiles...
► Artikel lesen
13.03.Indaptus Therapeutics, Inc. - 10-K, Annual Report1
12.03.Registration Is Now Open For Tribe Public's Webinar Event "Keys To The Kingdom: Unlocking The Power Of Your Immune System" Featuring Indaptus Therapeutics' CEO On Monday, March 17, 20251
04.03.Indaptus sichert neue Patente in Asien und Israel für Decoy-Plattform1
Weiter >>
30 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1